Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study

PLoS ONE

Volumn 12, Issue 6, 2017, Pages

  Ogawa, Chie ^a,b   Tsuchiya, Ken ^b,c   Tomosugi, Naohisa ^b,d   Kanda, Fumiyoshi ^a   Maeda, Kunimi ^a,b   Maeda, Teiryo ^a,b  

^a Maeda Institute of Renal Research   (Japan)

^b Biomarker Society INC   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; IRON SACCHARATE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON THERAPY; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OUTPATIENT; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TRANSFERRIN BLOOD LEVEL; AGED; BLOOD; HEMODIALYSIS; METABOLISM;

AGED; FEMALE; FERRITINS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TRANSFERRIN;

EID: 85021664213     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0179608     Document Type: Article

References (41)

1. Turenne MN, Cope EL, Porenta S, Mukhopadhyay P, Fuller DS, Jeffrey M, et al. Has Dialysis Payment Reform Led to Initial Racial Disparities in Anemia and Mineral Metabolism Management? J Am Soc Nephrol 2015; 26: 754-764. https://doi.org/10.1681/ASN.2013111232 PMID: 25300289.
2. Nakai S, Hanafusa N, Masakane I, Taniguchi M, Hamano T, Shoji T, et al. An Overview of Regular Dialysis Treatment in Japan (as of 31 December 2012). Therapeutic Apheresis and Dialysis 2014; 18: 535-602. https://doi.org/10.1111/1744-9987.12281 PMID: 25523509.
3. Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, et al. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 2010; 14:240-275. https://doi.org/10.1111/j.1744-9987.2010.00836.x PMID: 20609178.
4. Reis KA, Guz G, Ozdemir H, Erten Y, Atalay V, Bicik Z et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end stage renal disease. Int Heart J. 2005; 46: 255-264. PMID: 15876809.
5. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis. Circulation. 1997; 96: 3300-3307. https://doi.org/10.1161/01.CIR.96.10.3300 PMID: 9396420.
6. Dueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, et al. Iron Therapy, Advanced Oxidation Protein Products and Carotid Artery Intima-Media Thickness in End-Stage Renal Disease. Circulation. 2002; 106: 2212-2217. PMID: 12390950.
7. Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV. Infection Risk with Bolus versus Maintenance Iron Supplementation in Hemodialysis Patients. J Am Soc Nephrol. 2013; 24: 1151-1158. https://doi.org/10.1681/ASN.2012121164 PMID: 23787911.
8. Kato J. Kobune M, Nakamura T, Nakamura T, Takada K, Takimoto R, et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular cartinoma from chronic hepatitis C. J Gastroenterol. 2007; 42: 830-836. https://doi.org/10.1007/s00535-007-2095-z PMID: 17940836.
9. Anraku M, Kitamura K, Shintomo R, Takeuchi K, Ikeda H, Nagano J, et al. Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: A pilot study. Clin Biochemy 2008; 41: 1168-1174. https://doi.org/10.1016/j.clinbiochem.2008.07.007 PMID: 18692036.
10. Maruyama Y, Nakayama M, Yoshimura K, Nakano H, Yamamoto H, Yokoyama K, et al. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-20-deoxyguanosine levels. Nephrol Dial Transplant 2007; 22: 1407-1412. https://doi.org/10.1093/ndt/gfl789 PMID: 17264097.
11. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl (2011) 2012; 4: 292-298.
12. Eschbach JW, Cook JD, Scribner BH, Finch CA. Iron Balance in Hemodialysis Patients. Ann Intern Med. 1977; 87:710-713. PMID: 931207.
13. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif. 2004; 22:112-23. https://doi.org/10.1159/000074931 PMID: 14732819.
14. Tsukamoto T, Matsubara T, Akashi Y, Kondo M, Yanagita M. Annual Iron Loss Associated with Hemodialysis. Am J Nephrol. 2016; 43:32-8. https://doi.org/10.1159/000444335 PMID: 26885949.
15. Ganz T. Hepcidin-A regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Heamatol. 2006; 108: 1381-1387. https://doi.org/10.1016/j.beha.2004.08.020 PMID: 15737883.
16. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood. 2006; 108:1381-1387. https://doi.org/10.1182/blood-2005-10-4043 PMID: 16621968.
17. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011, 117, 4425-4433. https://doi.org/10.1182/blood-2011-01-258467 PMID: 21346250.
18. Nakanishi T, Kuragano T, Nanami M, Otaki Y, Nonoguchi H, Hasuike Y et al. Importance of Ferritin for Optimizing Anemia Therapy in Chronic Kidney Disease. Am J Nephrol 2010; 32: 439-446. https://doi.org/10.1159/000320733 PMID: 20881381.
19. Bross L, Zitterkoph J, Pithia J, Benner D, Rambod M, Kovesdy CP, et al. Association of Serum Total Iron-Binding Capacity and Its Changes Over Time with Nutritional and Clinical Outcomes in Hemodialysis Patients. Am J Nephrol 2009; 29:571-581. https://doi.org/10.1159/000191470 PMID: 19136818.
20. Ferrucci L, Semba RD, Guralnik JM, Ershler WB, Bandinelli S, Patel KV, et al. Proinflammatorystate, hepcidin, and anemia in older persons. Blood 2010; 115: 3810-3816. https://doi.org/10.1182/blood-2009-02-201087 PMID: 20081092.
21. Ali MAM, Luxton AW, Walker WHC. Serum ferritin concentration and bone marrow iron stores: A prospective study. Can Med Assoc J 1978; 118:945-946. PMID: 647567.
22. K/DOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47(Suppl 3): S58-S70.
23. Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R; ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: A position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant (2009) 24: 348-354. https://doi.org/10.1093/ndt/gfn653 PMID: 19037082.
24. Kliger SA, Foley NR, Goldfarb SD, Stuart L. Goldstein LS, Johansen K, et al. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis. 62(5):849-859. https://doi.org/10.1053/j.ajkd.2013.06.008 PMID: 23891356
25. Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood. 2009; 113: 5277-86. https://doi.org/10.1182/blood-2008-12-195651 PMID: 19293425
26. Eschbach JW, Cook JD, Scribner BH, Finch CA. Iron balance in hemodialysis patients. Ann Intern Med. 1977; 87: 710-3. PMID: 931207.
27. Nakanishi T, Kuragano T, Kaibe S, Nagasawa Y, Hasuike Y. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations? Clin Exp Nephrol (2012) 16: 819-826. https://doi.org/10.1007/s10157-012-0694-3 PMID: 23053592.
28. Rubab Z, Amin H, Abbas K, Hussain S, Ullah MI, Mohsin S. Serum Hepcidin Levels in Patients with End-Stage Renal Disease on Hemodialysis. Saudi J Kidney Dis Transpl 2015; 26(1):19-25. PMID: 25579711.
29. Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T. et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest. 2009; 39: 883-90. https://doi.org/10.1111/j.1365-2362.2009.02182.x PMID: 19563467.
30. Kuragano T, Shimonaka Y, Kida A, Furuta M, Nanami M, Otaki Y. et al. Determinants of Hepcidin in Patients on Maintenance Hemodialysis: Role of Inflammation. Am J Nephrol 2010; 31:534-540. https://doi.org/10.1159/000312381 PMID: 20484891.
31. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferemia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113: 1271-1276. https://doi.org/10.1172/JCI20945 PMID: 15124018.
32. Bregman DB, Morris D, Koch TA, He A, Goodnough LT, et al. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am. J. Hematol. 2013, 88, 97-101. https://doi.org/10.1002/ajh.23354 PMID: 23335357.
33. Takasawa K, Takaeda C, Maeda T, Ueda N, et al. Hepcidin-25, Mean Corpuscular Volume, and Ferritin as Predictors of Response to Oral Iron Supplementation in Hemodialysis Patients. Nutrients 2015; 7: 103-118. https://doi.org/10.3390/nu7010103 PMID: 25551249.
34. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1(Suppl 1): S4-S8. https://doi.org/10.2215/CJN.01490506 PMID: 17699374.
35. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010; 116:4754-4761. https://doi.org/10.1182/blood-2010-05-286260 PMID: 20826717.
36. Pasricha SR, Flecknoe-Brown SC, Allen KJ, Gibson PR, McMahon LP, Olynyk JK, et al. Diagnosis and management of iron deficiency anemia: A clinical update. Med J Aust 2010; 193:525-532. PMID: 21034387.
37. Akizawa T, Pisoni RL, Akiba T, Saito A, Fukuhara S, Asano Y, et al. Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS. Nephrol Dial Transplant 2008; 23: 3643-3653. https://doi.org/10.1093/ndt/gfn346 PMID: 18577535.
38. Usberti M, Gerardi G, Micheli A, Tira P, Bufano G, Gaggia P, et al. Effects of a vitamin E-bonded membrane and of glutathione on anemia and erythropoietin requirements in hemodialysis patients. J Nephrol. 2002 Sep-Oct; 15(5):558-64. PMID: 12455724.
39. Flynn PT, Allen WD, Johnson JG, White GJ. Oxidant Damage of the Lipids and Proteins of the Erythrocyte Membranes in Unstable Hemoglobin Disease. Evidence for the role of lipid peroxidation. J. Clin. Invest. 1983 1215-1223. https://doi.org/10.1172/JCI110870 PMID: 6853709.
40. Cristol J.-P., Bosc J.-Y., Badiou S., Leblanc M., Lorrho R., Descomps B. and Canaud B.. Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation. Nephrol Dial Transplant (1997) 12: 2312-2317. PMID: 9394317.
41. Hamano T, Fujii N, Hayashi T, Yamamoto H, Iseki K, Tsubakihara Y. Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry. Kidney Int Suppl 2015 Jun; 5(1):23-32. https://doi.org/10.1038/kisup.2015.6 PMID: 26097782.